Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CFO Kevin Patrick Moran Sells 2,239 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating) CFO Kevin Patrick Moran sold 2,239 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $10.97, for a total value of $24,561.83. Following the completion of the sale, the chief financial officer now directly owns 117,452 shares in the company, valued at $1,288,448.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Vanda Pharmaceuticals Price Performance

VNDA opened at $10.54 on Tuesday. Vanda Pharmaceuticals Inc. has a 1-year low of $9.24 and a 1-year high of $21.44. The stock’s 50 day simple moving average is $10.57 and its 200 day simple moving average is $11.42. The stock has a market cap of $595.40 million, a P/E ratio of 32.94 and a beta of 0.47.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Rating) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.10). Vanda Pharmaceuticals had a net margin of 6.79% and a return on equity of 3.65%. The business had revenue of $60.19 million for the quarter, compared to the consensus estimate of $58.00 million. During the same period last year, the firm posted $0.15 EPS. Research analysts expect that Vanda Pharmaceuticals Inc. will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Nisa Investment Advisors LLC lifted its position in Vanda Pharmaceuticals by 134.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 4,900 shares during the last quarter. CI Investments Inc. bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at approximately $107,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Vanda Pharmaceuticals by 28.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,342 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,606 shares during the last quarter. Wedge Capital Management L L P NC acquired a new position in Vanda Pharmaceuticals in the first quarter valued at approximately $117,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Vanda Pharmaceuticals in the first quarter worth $119,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 3rd.

About Vanda Pharmaceuticals

(Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Recommended Stories

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Want More Great Investing Ideas?

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.